<unk>  succinate is a potent anticholinergic and has a side-effect profile common to such drugs, including dry mouth, ataxia, urinary retention, drowsiness, memory problems, inability to concentrate, hallucinations, psychosis, and a marked increased sensitivity to external stimuli. Because of its relatively long elimination half-life (10–12 hours),<unk>  is associated with daytime/next-day drowsiness, grogginess, dry mouth, and tiredness when used as a hypnotic. The shorter elimination half-life of diphenhydramine (4–8 hours) may give it an advantage over<unk>  in this regard. Unlike with diphenhydramine, case reports of coma and rhabdomyolysis have been reported with<unk> . Toxicity<unk>  succinate is generally safe for administration to healthy adults. The median lethal dose () is estimated to be ~500 mg/kg in humans. Symptoms of overdose may include dry mouth, dilated pupils, insomnia, night terrors, euphoria, hallucinations, seizures, rhabdomyolysis, and death. Fatalities have been reported from<unk>  overdose. These have been characterized by coma, tonic-clonic (or grand mal) seizures and cardiorespiratory arrest. Children appear to be at a high risk for cardiorespiratory arrest. A toxic dose for children of more than 1.8 mg/kg has been reported. A 3-year-old child died 18 hours after ingesting 1000 mg<unk>  succinate. Rarely, an overdose results in rhabdomyolysis and acute kidney injury. Studies of<unk> 's carcinogenicity in mice and rats have produced positive results for both liver and thyroid cancer, especially in the mouse. The carcinogenicity of the drug in humans is not well studied, and the IARC lists the drug as "not classifiable as to its carcinogenicity to humans".
Doxylamine
Levopropylhexedrine
Difelikefalin
Halofantrine
Pentomone
Diallyllysergamide
Levomepromazine
Ethylnorepinephrine